The Pharma Data

NOVEMBER 30, 2020

Biohaven acquires exclusive global rights to a portfolio of novel, small-molecule CGRP antagonists. In addition, we have advanced zavegepant, our intra-nasal CGRP receptor antagonist, successfully through its first pivotal trial, also for the acute treatment of migraine. TOKYO and CAMBRIDGE, England , Dec.

Small Molecule 40

Small Molecule Licensing Licensing Clinical Trials 40

Drug Discovery World

APRIL 8, 2024

In December 2023, Pfizer announced that it had chosen to donate the rights of its royalties from the sale of Bavencio (avelumab) in the United States to the AACR, as an acknowledgment of the AACR’s dedication to sustained innovation in cancer research and treatment.

DNA 130

DNA Small Molecule Science Treatment 130

Drug Discovery World

APRIL 6, 2023

Science ↔ Survivor Program As mentioned previously, AACR has a Scientist↔Survivor Program. Its purpose is to build enduring partnerships between the leaders of the scientific, cancer survivor, and patient advocacy communities worldwide.

Small Molecule 130

Small Molecule Targeted Protein Degradation Clinical Trials Engineering 130

Drug Discovery World

JUNE 5, 2023

DDW’s Megan Thomas comments on the event. New approaches to partnering In this event in the Biotech track, Clive Cookson, Science Editor at the Financial Times, interviewed John McDonald, Corporate Vice President, Global R&D Business Development, Novo Nordisk.

Small Molecule 130

Small Molecule Treatment Science Disease 130

Drug Discovery World

APRIL 15, 2023

As the theme, Advancing the Frontiers of Cancer Science and Medicine , suggests, a number of announcements, results and presentations will take place at what is widely considered to be a flagship event for the cancer research community. Here are eight anticipated ‘curtain raisers’ in advance of the event: 1.

Virus 130

Virus Clinical Trials Trials Therapies 130

Drug Discovery World

NOVEMBER 1, 2022

Ground-breaking therapies . The company said: “As of the 28 September 2022, patients have been dosed with Auceliciclib, and dosing has completed for Cohorts 1 – 5 of the monotherapy dose escalation, and Cohorts 1a, 1b for the combination therapy arms with Temozolomide (TMZ). The research and academia landscape .

Drugs 130

Drugs Science Therapies Clinical Trials 130

The Pharma Data

NOVEMBER 8, 2021

“HER-MES is the first study that directly compared the therapeutic effects of an antibody and a small molecule in migraine prevention,” said Uwe Reuter, M.D., “The positive outcomes strengthen the efficacy and safety profile of erenumab as a migraine prevention treatment for patients with migraine.”

Therapies 52

Therapies FDA Approval Small Molecule Treatment 52

Drug Discovery World

OCTOBER 16, 2023

A company within this ecosystem is STORM Therapeutics, a clinical stage biotechnology company creating novel small molecule therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases. The university aims to identify treatments for life-threatening anti-microbial diseases and metabolic disorders.

Drugs 189

Drugs Science Therapies Targeted Protein Degradation 189

Drug Discovery World

APRIL 27, 2023

Research spotlight : In February 2023, Duke University co-investigators took a groundbreaking step in the treatment of geographic atrophy (GA), an advanced form of dry macular degeneration through the FDA approval of pegcetacoplan, the first ever FDA-approved treatment for GA.

Small Molecule 130

Small Molecule Science Drugs FDA Approval 130

Drug Target Review

JUNE 12, 2023

With 13 preclinical candidates and three AI-designed drugs currently undergoing clinical trials, Insilico is spearheading a revolution in cancer treatment and beyond. Can you provide a summary of the key findings and implications of the preclinical studies on ISM6331 for the treatment of advanced solid tumours?

Metabolic Stability 92

Metabolic Stability Clinical Trials Small Molecule Pharmacokinetics 92

The Pharma Data

JANUARY 13, 2021

Preliminary analyses showed no clinically meaningful differences in safety results between the dexpramipexole and placebo groups, with no serious adverse events and 96% of subjects completing the primary assessment phase. Background standard of care was inhaled corticosteroids in combination with a long-acting ?2 President and CEO of Knopp.

Trials 52

Trials Small Molecule Clinical Trials Treatment 52

Advarra

FEBRUARY 24, 2023

How do you know your experimental therapy is working? But what does “working” really mean when efficacy means something subjective, like quality of life, reduced psychiatric events, or less symptoms? All key questions to consider and address before the therapy even leaves the lab.

Clinical Trials 52

Clinical Trials Trials FDA Therapies 52

Drug Discovery World

APRIL 30, 2024

Reece Armstrong explores the potential and future opportunities for mRNA-based therapies. For instance, consider how at the end of 2018, the mRNA therapies market was valued at $3.43 We can see this versatility in the various treatments that are currently being researched.

Therapies 130

Therapies RNA Vaccine Small Molecule 130

The Pharma Data

DECEMBER 15, 2020

FDA Approves Klisyri (tirbanibulin) for the Treatment of Actinic Keratosis on the Face or Scalp. NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the U.S. BUFFALO, N.Y.,

FDA Approval 52

FDA Approval FDA Treatment Small Molecule 52

Drug Discovery World

SEPTEMBER 9, 2024

Vesper Bio has completed a Phase I study for its lead candidate, VES001, a potentially disease-modifying treatment for frontotemporal dementia patients with mutations in the progranulin gene (FTD(GRN)). Frontotemporal dementia is the most common cause of dementia in people under the age of 60.

Treatment 147

Treatment Pharmacokinetics Small Molecule Trials 147

The Pharma Data

AUGUST 30, 2021

The head-to-head study was designed to directly compare the efficacy of abrocitinib 200mg versus dupilumab 300mg, in adult participants on background topical therapy with moderate to severe atopic dermatitis (AD). The study will allow assessment of any difference in efficacy that may persist at month 6 of treatment. About Abrocitinib.

Small Molecule 52

Small Molecule Trials Treatment FDA 52

The Pharma Data

JANUARY 26, 2021

Food and Drug Administration’s Office of Orphan Products Development has granted Orphan Drug Designation to Uttroside-B , a small molecule chemotherapeutic for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer. (OTCQB: QBIO), announced today that the U.S. .

FDA 40

FDA Treatment Small Molecule Government 40

The Pharma Data

APRIL 23, 2021

European Commission approves GSK’s JEMPERLI (dostarlimab), the first anti-PD-1 therapy approved for recurrent or advanced endometrial cancer. The approval makes dostarlimab the first anti-PD-1 therapy available for endometrial cancer in Europe. For media and investors only. Issued: London UK. and 90.9% (95% CI; 73.7,

Therapies 52

Therapies Treatment Licensing Licensing 52

The Pharma Data

NOVEMBER 29, 2020

1 Meanwhile, these MDM2 inhibitors present some challenges, including dose-limiting hematological toxicities, thus the urgent need to develop new generation of MDM2-targeting therapies in the treatment of cancer. SUZHOU, China and ROCKVILLE, Md. , 29, 2020 /PRNewswire/ — Ascentage Pharma (6855.HK), Aguilar, A.; Bernard, D.;

Licensing 40

Licensing Licensing Small Molecule Clinical Trials 40

The Pharma Data

OCTOBER 6, 2021

The adverse event profile was generally consistent with other clinical safety data for COMIRNATY. At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. About Pfizer: Breakthroughs That Change Patients’ Lives.

Vaccine 52

Vaccine Small Molecule Government Therapies 52

Drug Discovery World

SEPTEMBER 26, 2024

The Drug Discovery in Scotland Forum showcased how Scotland is shaping drug discovery using approaches including traditional small molecules, therapeutic proteins, CRISPR/ RNAi and cell therapies, as well as how these are being used in 2D and 3D models.

Small Molecule 147

Small Molecule Drugs Therapies Disease 147

The Pharma Data

OCTOBER 1, 2021

Pfizer today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved CIBINQO ® (abrocitinib), an oral, once-daily, Janus kinase 1 (JAK1) inhibitor, for the treatment of moderate to severe atopic dermatitis (AD) in adults and adolescents aged 12 years and older with inadequate response to existing therapies.

Clinical Trials 52

Clinical Trials Small Molecule Trials Production 52

The Pharma Data

NOVEMBER 10, 2020

11, 2020 (GLOBE NEWSWIRE) — Calithera Biosciences, Inc. , (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced its participation at two upcoming healthcare investor conferences in November.

Small Molecule 40

Small Molecule Clinical Trials Production Treatment 40

The Pharma Data

JANUARY 3, 2021

As compared to treatment with cabozantinib, the combination of telaglenastat and cabozantinib did not meet the primary endpoint of improving progression free survival (PFS) in the study population. Sixty-two percent of patients were treated with prior PD(L)-1 containing therapy, and the arms were well balanced. Median PFS was 9.2

Trials 52

Trials Clinical Trials Small Molecule Therapies 52

The Pharma Data

OCTOBER 25, 2020

Roxadustat is approved for the treatment of anemia associated with CKD in Japan in dialysis dependent patients and in China in both dialysis dependent and non-dialysis dependent patients. In the study, the drug demonstrated statistically significant and clinically meaningful efficacy and a favorable adverse event and tolerability profile.

Vaccine 52

Vaccine Clinical Trials Trials Virus 52

The Pharma Data

MARCH 4, 2021

Our goal is to one day bring new treatment options that provide greater seizure control, tolerability and function to DS and LGS patients around the world.”. Advancing New Treatment Options for DS and LGS Patients. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines.

Treatment 52

Treatment Pharmaceutical Companies Clinical Trials Licensing 52

Elrig

JUNE 4, 2024

Zahra Jawad is the founder and CEO of Creasallis, a company focused on antibody remodeling to improve penetration and treatment of solid tumours. The focus used to be more on small molecules, but we’re now starting to see antibody and cell therapeutics. Have you attended ELRIG before?

Small Molecule 52

Small Molecule Science Drugs Research 52

The Pharma Data

OCTOBER 27, 2020

Mirati Therapeutics is a San Diego -based late-stage biotechnology company relentlessly focused on translating drug discovery and research into new treatments for patients by advancing and delivering novel therapeutics that target the genetic and immunologic drivers of cancer. About Mirati Therapeutics. Forward-Looking Statements.

Small Molecule 52

Small Molecule Immune Response Clinical Development Clinical Trials 52

The Pharma Data

DECEMBER 9, 2020

About Oncternal Therapeutics Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. SAN DIEGO, Dec. 09, 2020 (GLOBE NEWSWIRE) — Oncternal Therapeutics, Inc. More information is available at.

Clinical Trials 52

Clinical Trials Small Molecule Therapies Treatment 52

The Pharma Data

DECEMBER 14, 2020

The global GBM treatment market is projected to reach $3.3 The ability of a drug candidate to cross the blood brain barrier is of critical importance in treatment outcomes for CNS and brain cancers. At the stage of GBM relapse and recurrence, no effective therapy strategies currently exist.

DNA 52

DNA Clinical Trials Drugs Therapies 52

The Pharma Data

OCTOBER 21, 2020

We look forward to advancing clinical development of KB-0742 to establish the dose, safety and efficacy of this investigational therapy as a potential treatment for MYC-amplified tumors.”. The current treatment for prostate cancer consists of targeting AR activity, a key driver of prostate cancer. “The SAN MATEO, Calif.,

Small Molecule 40

Small Molecule Clinical Trials Clinical Development Treatment 40

The Pharma Data

AUGUST 29, 2020

Oral, investigational complement factor B inhibitor LNP023 substantially improved hematological response as add-on therapy to eculizumab. All patients required RBC transfusions prior to starting LNP023 treatment. “In Peffault de Latour.

Treatment 52

Treatment Disease Small Molecule Production 52

The Pharma Data

JANUARY 7, 2021

NASDAQ: GLTO) a NASDAQ listed biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced the appointment of Dr. Anne Prener to its Board of Directors. “We a gene therapy company focused on eye diseases. Actual events or results may differ materially from Galecto’s expectations.

Small Molecule 52

Small Molecule Clinical Development Production Science 52

The Pharma Data

JANUARY 18, 2021

The fireside chat will be available for 90+ days following the event at: [link] 5 69. Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to treat cancers. for the treatment of post-herpetic neuralgia. for the treatment of post-herpetic neuralgia.

Small Molecule 40

Small Molecule Clinical Trials Trials Therapies 40

The Pharma Data

JANUARY 13, 2021

Dr. Lederman continued, “Despite the recognized promise of anti-CD40-ligand mAb therapy, first generation anti-CD40-ligand mAbs were limited because their crystallizable fragment (Fc) domain interacted with a cell surface receptor called Fc?RII, RII, which resulted in an increased risk of thrombosis. 1 Lederman, S.

Pharmaceuticals 52

Pharmaceuticals Small Molecule Vaccine Protein Expression 52

The Pharma Data

NOVEMBER 22, 2020

Omecamtiv mecarbil is an investigational cardiac myosin activator, developed for the potential treatment of heart failure with reduced ejection fraction (HFrEF), and was recently studied in GALACTIC-HF, a positive Phase 3 cardiovascular outcomes clinical trial. Terms of Termination. GALACTIC-HF : Results and Next Steps.

Clinical Trials 52

Clinical Trials Licensing Licensing Trials 52

The Pharma Data

OCTOBER 26, 2020

Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced the Company will present at the ROTH Capital Partners 2020 MedTech Innovation Forum on Wednesday, October 28, 2020. SAN JOSE, Calif. , About Aridis Pharmaceuticals, Inc.

Pharmaceuticals 52

Pharmaceuticals Virus Hospitals Clinical Trials 52